Teratozoospermia (Abnormal Sperm Morphology)

Teratozoospermia is a seminal anomaly characterized by the presence of an abnormally high percentage of morphologically abnormal spermatozoa in the ejaculate, as defined by strict criteria for normal sperm morphology. In veterinary theriogenology, normal sperm morphology is typically defined by the presence of a normal head (smooth, oval, with a well-defined acrosome), a distinct neck, a straight midpiece with a cytoplasmic droplet at the proximal or distal end (depending on maturation), and a single, straight, tapering tail. The threshold for teratozoospermia varies by species; in dogs, a normal ejaculate typically contains >80% morphologically normal sperm, and teratozoospermia is diagnosed when the percentage of abnormal forms exceeds 20-30%. In cats, normal morphology is often >60-70%, with teratozoospermia defined when abnormal forms exceed 30-40%. Teratozoospermia is a common cause of reduced fertility, as abnormal spermatozoa are often incapable of fertilization or may result in early embryonic death. The condition may be primary (due to testicular or epididymal dysfunction) or secondary (due to environmental, infectious, or iatrogenic factors). It is often accompanied by other seminal anomalies, such as oligozoospermia (reduced sperm count) or asthenozoospermia (reduced sperm motility), collectively referred to as oligoasthenoteratozoospermia (OAT syndrome).

The etiology of teratozoospermia is multifactorial and can be classified into congenital, genetic, infectious, hormonal, environmental, and iatrogenic causes. Congenital causes include testicular hypoplasia, segmental aplasia of the epididymis, and defects in spermatogenesis due to chromosomal abnormalities (e.g., XXY syndrome, Robertsonian translocations). Genetic factors include inherited defects in sperm head shape (e.g., knobbed acrosome, pear-shaped head) or tail abnormalities (e.g., coiled tail, double tail), which are often breed-specific. Infectious agents, such as Brucella canis, Mycoplasma spp., Ureaplasma spp., and canine herpesvirus, can cause epididymitis and orchitis, leading to abnormal sperm maturation and morphology. Hormonal imbalances, including hypothyroidism, hyperadrenocorticism, and deficiencies in testosterone or follicle-stimulating hormone (FSH), can disrupt spermatogenesis. Environmental factors include heat stress (elevated scrotal temperature), exposure to toxins (e.g., lead, pesticides, mycotoxins), and poor nutrition (e.g., zinc deficiency). Iatrogenic causes include the use of anabolic steroids, glucocorticoids, or certain antibiotics (e.g., nitrofurantoin) that impair spermatogenesis. Additionally, prolonged sexual rest or excessive ejaculation frequency can affect sperm morphology.

Teratozoospermia is a common finding in both canine and feline male infertility cases. In dogs, the prevalence of teratozoospermia in subfertile males is reported to be between 20% and 40%, depending on the breed and the criteria used. Certain breeds, such as the Boxer, German Shepherd, and Bullmastiff, are predisposed to specific sperm defects, including the 'Dag defect' (a coiled tail defect) and knobbed acrosomes. In cats, teratozoospermia is frequently observed in purebred breeds, particularly Persians and Himalayans, with a prevalence of up to 30% in some populations. Age is a significant factor; young males may exhibit transient teratozoospermia during puberty, while aged males may show degenerative changes. Seasonal variations have been noted in some breeds, with poorer morphology during hot summer months. Males with a history of cryptorchidism or testicular neoplasia are at higher risk. Additionally, males housed in stressful environments or with poor breeding management (e.g., infrequent or excessive ejaculation) are more likely to exhibit abnormal sperm morphology.

The pathophysiology of teratozoospermia involves disruption at any stage of spermatogenesis, spermiogenesis, or sperm maturation in the epididymis. Spermatogenesis occurs in the seminiferous tubules, where spermatogonia undergo mitotic and meiotic divisions to produce spermatids. Spermiogenesis is the final differentiation of spermatids into mature spermatozoa, involving acrosome formation, nuclear condensation, and flagellar development. Any disruption in the hormonal milieu (e.g., low FSH or testosterone) or direct damage to Sertoli cells (e.g., from toxins or heat) can lead to abnormal sperm head shape, such as microcephaly, macrocephaly, or pyriform heads. Abnormalities in the acrosome (e.g., knobbed acrosome) result from defective Golgi apparatus function during spermiogenesis. Tail defects, such as coiled or bent tails, often arise from abnormal axonemal development or dysfunction of the mitochondrial sheath in the midpiece. Epididymal maturation is crucial for the acquisition of motility and the shedding of the cytoplasmic droplet; failure of this process can result in proximal cytoplasmic droplets, which are considered abnormal. Additionally, oxidative stress, due to an imbalance between reactive oxygen species (ROS) and antioxidants in the seminal plasma, can cause DNA damage and lipid peroxidation of the sperm membrane, leading to morphological abnormalities. Inflammatory conditions, such as orchitis or epididymitis, can cause leukocytic infiltration and release of cytokines, further impairing spermatogenesis.

Intrinsic predisposing factors include age (both young and old), breed (e.g., Boxers, German Shepherds, Persians), genetic predisposition (e.g., inherited defects), and concurrent reproductive disorders such as cryptorchidism, testicular neoplasia, or prostatitis. Hormonal imbalances, including hypothyroidism, hyperadrenocorticism, and diabetes mellitus, can also predispose to teratozoospermia. Extrinsic factors include environmental heat stress (e.g., high ambient temperature, fever), poor nutrition (e.g., deficiencies in zinc, selenium, vitamin E), exposure to environmental toxins (e.g., pesticides, heavy metals), and iatrogenic causes such as the administration of glucocorticoids, anabolic steroids, or chemotherapeutic agents. Stress, whether physical (e.g., transportation, injury) or psychological (e.g., overcrowding, changes in social hierarchy), can elevate cortisol levels, which negatively affect spermatogenesis. Poor breeding management, such as prolonged sexual rest (leading to accumulation of senescent sperm) or excessive ejaculation (leading to immature sperm), can also contribute. Additionally, inadequate collection techniques (e.g., contamination with urine or water) can cause osmotic damage to sperm.

The primary clinical sign of teratozoospermia is reduced fertility, which may manifest as failure to conceive, prolonged inter-estrus intervals in bitches, or small litter sizes. In many cases, the male may appear clinically healthy with normal libido and mating behavior. Physical examination may reveal testicular abnormalities, such as small, soft, or asymmetrical testes, or epididymal enlargement. In some cases, there may be evidence of orchitis or epididymitis, including pain, swelling, and fever. Semen evaluation is essential for diagnosis; the ejaculate may appear normal in volume and color, but microscopic examination reveals a high percentage of abnormal spermatozoa. The abnormalities may be classified as primary (affecting the head, acrosome, or midpiece) or secondary (affecting the tail). In severe cases, the male may also exhibit oligozoospermia or azoospermia. Behavioral signs are uncommon, but some males may show reluctance to mate due to pain from testicular or epididymal disease.

Differential diagnoses for teratozoospermia include other seminal anomalies such as oligozoospermia (low sperm count), asthenozoospermia (poor motility), azoospermia (absence of sperm), and necrozoospermia (dead sperm). These conditions may occur concurrently, and a thorough semen analysis is necessary to differentiate them. Other causes of male infertility include obstructive azoospermia (e.g., due to epididymal obstruction), retrograde ejaculation, and ejaculatory failure. Infectious diseases such as brucellosis (Brucella canis) can cause epididymitis and orchitis, leading to abnormal sperm morphology. Hormonal disorders, including hypothyroidism and hyperadrenocorticism, can also affect sperm quality. Testicular neoplasia (e.g., Sertoli cell tumor, seminoma) may cause hormonal imbalances and sperm abnormalities. Additionally, iatrogenic causes such as recent administration of glucocorticoids or anabolic steroids should be considered. A thorough history, physical examination, and additional diagnostic tests (e.g., hormone assays, ultrasound, culture) are necessary to rule out these conditions.

The diagnostic algorithm for teratozoospermia begins with a complete history, including breeding history, previous fertility, and any systemic illnesses or medications. A thorough physical examination should be performed, with particular attention to the testes, epididymides, prostate, and scrotum. Semen collection is the cornerstone of diagnosis; in dogs, manual stimulation is used, while in cats, an artificial vagina or electroejaculation may be required. The ejaculate should be evaluated immediately for volume, color, pH, and sperm concentration. A sperm morphology assessment should be performed using a stained smear (e.g., Diff-Quik, eosin-nigrosin) and evaluated under oil immersion (1000x). At least 100-200 spermatozoa should be counted and classified as normal or abnormal, with abnormalities categorized by region (head, midpiece, tail). If teratozoospermia is confirmed, further diagnostic tests may include: (1) semen culture and sensitivity to rule out bacterial infection; (2) serology for Brucella canis; (3) hormonal assays (testosterone, FSH, LH, thyroid hormones); (4) testicular ultrasound to assess parenchymal architecture; (5) testicular biopsy if neoplasia or severe degeneration is suspected; and (6) genetic testing for known inherited defects. The diagnostic workup should be systematic to identify the underlying cause and guide treatment.

Laboratory findings in teratozoospermia are primarily based on semen analysis. Semen volume is typically normal, but sperm concentration may be reduced (oligozoospermia) in some cases. Sperm motility may be normal or reduced (asthenozoospermia). The key finding is an increased percentage of morphologically abnormal spermatozoa, which may include head defects (e.g., pyriform, microcephalic, macrocephalic, detached heads), acrosomal defects (e.g., knobbed acrosome), midpiece defects (e.g., proximal or distal cytoplasmic droplets, bent midpiece), and tail defects (e.g., coiled, bent, or double tails). Hematology and serum biochemistry are usually unremarkable unless there is an underlying systemic disease. If orchitis or epididymitis is present, there may be leukocytosis and elevated acute-phase proteins. Hormonal assays may reveal low testosterone or FSH levels, indicating testicular dysfunction. Thyroid hormone levels (T4, TSH) may be abnormal in hypothyroidism. Semen culture may yield bacterial growth, and serology for Brucella canis should be performed. In cases of suspected genetic defects, cytogenetic analysis or specific genetic tests may be indicated.

Imaging modalities are useful in evaluating the reproductive tract of males with teratozoospermia. Testicular ultrasonography is the primary imaging tool; it can assess testicular size, echotexture, and the presence of masses or cysts. In teratozoospermia, the testes may appear normal or show diffuse hyperechogenicity (indicative of fibrosis) or hypoechogenicity (indicative of edema or inflammation). The epididymides should also be evaluated for enlargement or cystic changes. Prostatic ultrasonography can detect prostatitis or prostatic cysts, which may contribute to seminal abnormalities. In cases of suspected obstruction, contrast radiography (e.g., vasography) may be performed, but this is rarely indicated. Advanced imaging such as CT or MRI is not routinely used but may be helpful in evaluating testicular neoplasia or complex anatomical abnormalities. Scrotal thermography has been used in research settings to assess scrotal temperature gradients, but it is not widely available in clinical practice.

Cytological evaluation of semen is the primary diagnostic tool for teratozoospermia. A stained smear (e.g., Diff-Quik, eosin-nigrosin) allows for detailed morphological assessment of spermatozoa. The presence of >20-30% abnormal forms confirms the diagnosis. In addition to sperm morphology, the presence of leukocytes, erythrocytes, or epithelial cells in the ejaculate may indicate inflammation or infection. Testicular fine-needle aspiration (FNA) can be performed to evaluate spermatogenic activity; cytology may reveal a reduced number of spermatogenic cells or the presence of abnormal cells. Testicular biopsy is more invasive but provides a definitive histopathological diagnosis. Histopathological findings may include seminiferous tubular degeneration, atrophy, fibrosis, or neoplasia. Special stains, such as periodic acid-Schiff (PAS), can highlight acrosomal abnormalities. In cases of epididymal disease, biopsy of the epididymis may reveal inflammation or obstruction. Histopathology is particularly useful in distinguishing between obstructive and non-obstructive causes of teratozoospermia.

The treatment of teratozoospermia depends on the underlying cause. If an infectious etiology is identified, appropriate antibiotics should be administered based on culture and sensitivity. For Brucella canis, treatment is not recommended due to zoonotic risk and poor response; euthanasia may be considered. Hormonal imbalances should be corrected; for example, hypothyroidism is treated with levothyroxine (0.02 mg/kg PO q12h), and hyperadrenocorticism is managed with trilostane or mitotane. If testicular neoplasia is present, surgical removal (castration) is indicated. In cases of idiopathic teratozoospermia, supportive therapy may include antioxidants (e.g., vitamin E 400-800 IU/day, selenium 0.1-0.3 mg/kg/day, L-carnitine 100-200 mg/kg/day) to reduce oxidative stress. GnRH therapy (e.g., deslorelin implant) has been used to stimulate spermatogenesis in some cases, but results are variable. Management of environmental factors, such as reducing heat stress and improving nutrition, is essential. In cases of severe teratozoospermia with no identifiable cause, the prognosis for fertility is poor, and the use of assisted reproductive techniques (e.g., artificial insemination with fresh or frozen semen, intracytoplasmic sperm injection) may be considered, although success rates are low.

The prognosis for teratozoospermia varies depending on the underlying cause and severity. If the condition is due to a reversible cause, such as heat stress or a temporary infection, the prognosis is good, and sperm morphology may improve within 60-70 days (the duration of spermatogenesis and epididymal transit). If the cause is genetic or congenital, the prognosis is poor, and the male may be permanently infertile. In cases of testicular degeneration or neoplasia, the prognosis is guarded. The presence of a high percentage of primary abnormalities (e.g., head defects) is associated with a poorer prognosis than secondary abnormalities (e.g., tail defects). Additionally, if teratozoospermia is accompanied by oligozoospermia or asthenozoospermia, the prognosis for natural conception is reduced. In breeding animals, the prognosis for future fertility should be discussed with the owner, and alternative breeding strategies (e.g., artificial insemination with a higher sperm dose) may be recommended.

Follow-up for teratozoospermia involves serial semen evaluations to monitor response to treatment. Semen should be collected and evaluated every 60-70 days (one spermatogenic cycle) to assess improvement. If an underlying cause has been identified and treated, repeat semen analysis should be performed after the expected duration of spermatogenesis. For males receiving antioxidant therapy, a re-evaluation after 2-3 months is recommended. In breeding animals, a breeding soundness examination should be performed before each breeding season. If the male is used for artificial insemination, the semen should be evaluated for morphology before each collection. Additionally, the owner should be advised to monitor the male for any signs of systemic illness or reproductive tract disease. If the male is not intended for breeding, castration may be recommended to prevent the transmission of genetic defects.

Clinical pearls: (1) Always evaluate sperm morphology on a properly stained smear and count at least 100 spermatozoa; (2) Distinguish between primary and secondary abnormalities, as primary abnormalities are more significant; (3) Consider the effect of sexual rest; a second ejaculate after 1-2 days may have better morphology; (4) In cats, use a consistent collection method (e.g., electroejaculation) as morphology can vary with collection technique; (5) Always rule out Brucella canis in any breeding male with teratozoospermia. Pitfalls: (1) Failing to perform a thorough physical examination, which may miss testicular neoplasia or orchitis; (2) Overinterpreting a single semen sample; multiple samples are needed to confirm teratozoospermia; (3) Ignoring the impact of stress or recent illness on sperm morphology; (4) Using an inappropriate stain or improper fixation, which can artifactually alter sperm morphology; (5) Assuming that teratozoospermia is always permanent; some causes are reversible.

Current drug protocols for teratozoospermia are primarily supportive and aimed at treating underlying causes. For bacterial infections, antibiotics such as enrofloxacin (5-10 mg/kg PO q12h for 14-28 days) or doxycycline (5-10 mg/kg PO q12h for 14-28 days) may be used, based on culture and sensitivity. For Brucella canis, no effective treatment is recommended; euthanasia is advised. For hypothyroidism, levothyroxine is administered at 0.02 mg/kg PO q12h, with monitoring of T4 levels. For hyperadrenocorticism, trilostane (2-6 mg/kg PO q24h) or mitotane (50 mg/kg/day initially, then 25-50 mg/kg/week) may be used. Antioxidant supplementation includes vitamin E (400-800 IU/day), selenium (0.1-0.3 mg/kg/day), L-carnitine (100-200 mg/kg/day), and omega-3 fatty acids (e.g., fish oil 1000 mg/day). GnRH therapy, such as deslorelin (4.7 mg implant SC), may be used to stimulate spermatogenesis, but its efficacy is variable. In cases of testicular neoplasia, surgical castration is the treatment of choice. Supportive care includes maintaining optimal body condition, providing a balanced diet, and minimizing stress.

Evidence-based literature on teratozoospermia in dogs and cats is limited but growing. Studies have reported breed-specific sperm defects, such as the 'Dag defect' in dogs, which is inherited and associated with poor fertility. Research has shown that heat stress can cause transient teratozoospermia, with recovery after 60-70 days. Antioxidant therapy has been shown to improve sperm morphology in some cases of idiopathic teratozoospermia, but large randomized controlled trials are lacking. The use of GnRH implants has been investigated in dogs with oligozoospermia, with some studies showing improvement in sperm quality. Consensus guidelines from the Society for Theriogenology recommend a thorough diagnostic workup for males with teratozoospermia, including semen culture, hormonal assays, and testicular ultrasound. The European Society for Small Animal Reproduction (EVSSAR) has published guidelines on semen evaluation, emphasizing the importance of standardized morphology assessment. Overall, the evidence base is limited, and more research is needed to establish evidence-based treatment protocols.